Cytoreductive nephrectomy: identifying an ideal candidate based on preoperative predictive factors
Authors:
Vladimír Študent ml. 1; Hana Študentová 2
Authors‘ workplace:
Urologická klinika FN a LF UP Olomouc
1; Onkologická klinika FN a LF UP Olomouc
2
Published in:
Ces Urol 2022; 26(1): 13-28
Category:
Review articles
Overview
Treatment of metastatic renal cell carcinoma (mRCC) has changed dramatically in recent years. Targeted therapy (TT) and, more recently, immunotherapy in the form of immune checkpoint inhibitors (ICIs) have brought about a dramatic prolongation of the overall survival (OS) of patients. The urologist‘s role in mRCC is associated with cytoreductive nephrectomy (CN), which aims to alleviate symptoms or prolong OS. The oncological benefits of CN have recently been questioned through two prospective randomized studies, CARMENA and SURTIME. The situation is less clear today because all retrospective studies have confirmed the oncological importance of CN in the treatment of TT, but a new systemic treatment for mRCC is being used (ICIs). The main problem remains the correct selection of patients suitable for CN. At the time of TT, it was already clear that CN is not beneficial for all patients with mRCC. This article aims to present individual preoperative factors that could help in the correct selection of CN and discuss the surgical aspects of CN execution.
Keywords:
predictive factors – Metastatic renal cell carcinoma – cytoreductive nephrectomy
Sources
1. Incidence a mortalita C64 – ZN ledviny mimo pánvičku. [online]. Epidemiologie zhoubných nádorů v České republice. ÚZIS. [vid 6. 1. 2022]. Dostupné z: https://www.svod.cz.
2. Soares A, Maia MC, Vidigal F, Marques Monteiro FS. Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: How to Apply New Evidence in Clinical Practice. Oncology. 2020; 98(1): 1–9. doi:10.1159/000502778.
3. Howlader N, Noone AM, Krapcho M (eds). SEER Cancer Statistics Review (CSR) 1975-2018. [online]. Bethesda, MD [vid. 6. 1. 2022]. Dostupné z: https://seer.cancer.gov/csr/1975_2018/.
4. Middleton RG. Surgery for Metastatic Renal Cell Carcinoma. J Urol. 1967; 97(6): 973–977. doi:10.1016/ S0022-5347(17)63157-4.
5. Šámal V, Richter I, Paldus V, Jirásek T, Mečl J. Radiologická regrese metastatického renálního karcinomu po biologické léčbě sunitinibem - kazuistika a přehled literatury. Ces Urol. 2019; 23(4): 341–346.
6. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma. J Clin Oncol. 1999; 17(8): 2530–2530. doi:10.1200/ JCO.1999. 17. 8.2530
7. Heng DYC, Xie W, Regan MM, et al. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study. J Clin Oncol. 2009; 27(34): 5794–5799. doi:10.1200/JCO.2008. 21. 4809.
8. Sobotka R, Tomáš H, Zemanová M. Zásadní význam chirurgické léčby u karcinomu ledvin, možnosti biologické léčby. Čas Lék čes. 2011; 150: 156–160.
9. Finke JH, Rayman PA, Ko JS, Bradley JM, Gendler SJ, Cohen PA. Modification of the Tumor Microenvironment as a Novel Target of Renal Cell Carcinoma Therapeutics. Cancer J. 2013; 19(4): 353–364. doi:10.1097/ PPO.0b013e31829da0ae.
10. Lahn M, Fisch P, Kouml;hler G, et al. Pro‑Inflammatory and T Cell Inhibitory Cytokines Are Secreted at High Levels in Tumor Cell Cultures of Human Renal Cell Carcinoma. Eur Urol. 1999; 35(1): 70–80. doi:10.1159/000019821.
11. Bellardita L, Rancati T, Alvisi MF, et al. Predictors of health‑related quality of life and adjustment to prostate cancer during active surveillance. Eur Urol. 2013; 64(1): 30–36. doi:10.1016/j.eururo.2013. 01. 009.
12. Gatenby RA, Gawlinski ET, Tangen CM, Flanigan RC, Crawford ED. The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy. Cancer Res. 2002;62(18):5218-5222.
13. de Riese W, Goldenberg K, Allhoff E, et al. Metastatic renal cell carcinoma (RCC): Spontaneous regression, long‑term survival and late recurrence. Int Urol Nephrol. 1991; 23(1): 13–25. doi:10.1007/BF02549723.
14. Študentová H. Algoritmus léčby metastatického renálního karcinomu ledviny. Urol. praxi. 2011; 12(3): 152–157.
15. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy Followed by Interferon Alfa-2 b Compared with Interferon Alfa-2 b Alone for Metastatic Renal‑Cell Cancer. N Engl J Med. 2001; 345(23): 1655–1659. doi:10.1056/NEJMoa003013.
16. Mickisch G, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon‑alfa‑based immunotherapy compared with interferon alfa alone in metastatic renal‑cell carcinoma: a randomised trial. Lancet. 2001; 358(9286): 966–970. doi:10.1016/S0140-6736(01)06103-7.
17. Larcher A, Wallis CJD, Bex A, et al. Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates? Eur Urol Oncol. 2019; 2(4): 365–378. doi:10.1016/j.euo.2019. 04. 007.
18. Méjean A, Ravaud A, Thezenas S, et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal‑Cell Carcinoma. N Engl J Med. 2018; 379(5): 417–427. doi:10.1056/NEJMoa1803675.
19. Bex A, Mulders P, Jewett M, et al. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib. JAMA Oncol. 2019; 5(2): 164. doi:10.1001/jamaoncol.2018.5543.
20. Singla N, Hutchinson RC, Ghandour RA, et al. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database. Urol Oncol Semin Orig Investig. 2020; 38(6): 604.e9–604.e17. doi:10.1016/j.urolonc.2020. 02. 029.
21. Bakouny Z, Xie W, Dudani S, et al. Cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or targeted therapy (TT): A propensity score‑based analysis. J Clin Oncol. 2020; 38(6_suppl): 608–608. doi:10.1200/JCO.2020. 38. 6_suppl.608.
22. Poprach A, Holanek M, Chloupkova R, et al. Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy–Data from the National Renis Registry. Cancers (Basel). 2020; 12(10): 2911. doi:10.3390/cancers12102911.
23. Ljungberg B, Albiges L, Abu‑Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. Eur Urol. 2019; 75(5): 799–810. doi:10.1016/j.eururo.2019. 02. 011.
24. Mejean A, Thezenas S, Chevreau C, et al. Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): Update on Carmena trial with focus on intermediate IMDC‑risk population. J Clin Oncol. 2019; 37(15_suppl): 4508–4508. doi:10.1200/JCO.2019. 37. 15_suppl.4508.
25. Heng DYC, Wells JC, Rini BI, et al. Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2014; 66(4): 704–710. doi:10.1016/j.eururo.2014. 05. 034.
26. Silagy AW, Kotecha RR, Weng S, et al. Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma. Cancer. 2021; 127(21): 3946–3956. doi:10.1002/cncr.33790
27. Shuch B, La Rochelle JC, Wu J, et al. Performance status and cytoreductive nephrectomy. Cancer. 2008; 113(6): 1324–1331. doi:10.1002/cncr.23708.
28. Ohno Y, Nakashima J, Ohori M, et al. Clinical variables for predicting metastatic renal cell carcinoma patients who might not benefit from cytoreductive nephrectomy: neutrophil‑to‑lymphocyte ratio and performance status. Int J Clin Oncol. 2014; 19(1): 139–145. doi:10.1007/s10147-012-0514-5.
29. Pierorazio PM, McKiernan JM, McCann TR, Mohile S, Petrylak D, Benson MC. Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed. BJU Int. 2007; 100(4): 755–759. doi:10.1111/j.1464-410X.2007.07108.x.
30. Capitanio U, Abdollah F, Matloob R, et al. Effect of number and location of distant metastases on renal cell carcinoma mortality in candidates for cytoreductive nephrectomy: Implications for multimodal therapy. Int J Urol. 2013; 20(6): 572–579. doi:10.1111/iju.12004.
31. Yoon H‑J, Paeng JC, Kwak C, et al. Prognostic implication of extrarenal metabolic tumor burden in advanced renal cell carcinoma treated with targeted therapy after nephrectomy. Ann Nucl Med. 2013; 27(8): 748–755. doi:10.1007/s12149-013-0742-4.
32. de Bruijn RE, Nijkamp J, Noe A, et al. Baseline tumor volume in assessing prognosis of patients with intermediate‑risk synchronous metastatic renal cell carcinoma. Urol Oncol Semin Orig Investig. 2016; 34(6): 258.e7–258.e13. doi:10.1016/j.urolonc.2015. 12. 007.
33. Blute ML, Ziemlewicz TJ, Lang JM, et al. Metastatic Tumor Burden Does Not Predict Overall Survival Following Cytoreductive Nephrectomy for Renal Cell Carcinoma: a Novel 3-Dimensional Volumetric Analysis. Urology. 2017; 100: 139–144. doi:10.1016/j.urology.2016. 09. 016.
34. Guo B, Liu S, Wang M, Hou H, Liu M. The role of cytoreductive nephrectomy in renal cell carcinoma patients with liver metastasis. Bosn J Basic Med Sci. July 2020. doi:10.17305/bjbms.2020.4896.
35. Massari F, Di Nunno V, Guida A, et al. Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study. Clin Genitourin Cancer. 2021; 19(1): 32–40. doi:10.1016/j.clgc.2020. 06. 003.
36. Sharma P, Zargar‑Shoshtari K, Caracciolo JT, et al. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Urol Oncol Semin Orig Investig. 2015; 33(8): 339.e17–339.e23. doi:10.1016/j.urolonc.2015. 01. 011.
37. Psutka SP. Personalizing preoperative risk stratification and refining patient selection for cytoreductive nephrectomy in metastatic renal cell carcinoma. Cancer. 2020; 126(17): 3912–3915. doi:10.1002/cncr.32993.
38. Ito H, Shioi K, Murakami T, et al. C‑reactive protein in patients with advanced metastatic renal cell carcinoma: Usefulness in identifying patients most likely to benefit from initial nephrectomy. BMC Cancer. 2012; 12(1): 337. doi:10.1186/1471-2407-12-337.
39. Sakai I, Miyake H, Hinata N, Fujisawa M. Improved survival in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy in the era of targeted therapy. Int J Clin Oncol. 2014; 19(4): 674–678. doi:10.1007/s10147-013-0612-z.
40. Baum YS, Patil D, Huang JH, et al. Elevated preoperative neutrophil‑to‑lymphocyte ratio may be associated with decreased overall survival in patients with metastatic clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. Asian J Urol. 2016; 3(1): 20–25. doi:10.1016/j.ajur.2015. 09. 004.
41. Peyton CC, Abel EJ, Chipollini J, et al. The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy. Eur Urol Focus. 2020; 6(1): 104–111. doi:10.1016/j. euf.2018. 08. 023.
42. Day D, Kanjanapan Y, Kwan E, et al. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil‑to‑lymphocyte ratio in patients with metastatic renal cell carcinoma. Intern Med J. 2016; 46(11): 1291–1297. doi:10.1111/imj.13202.
43. Gu L, Ma X, Xie Y, et al. Pretreatment Lymphocyte to Monocyte Ratio is an Independent Prognostic Factor in Metastatic Clear Cell Renal Cell Carcinoma. Clin Genitourin Cancer. 2017; 15(3): e369–e377. doi:10.1016/j.clgc.2016. 12. 001.
44. Margulis V, Shariat SF, Rapoport Y, et al. Development of Accurate Models for Individualized Prediction of Survival After Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. Eur Urol. 2013; 63(5): 947–952. doi:10.1016/j.eururo.2012. 11. 040.
45. Corcoran AT, Kaffenberger SD, Clark PE, et al. Hypoalbuminaemia is associated with mortality in patients undergoing cytoreductive nephrectomy. BJU Int. 2015; 116(3): 351–357. doi:10.1111/bju.12897.
46. Lee H, Kim YJ, Hwang EC, et al. Preoperative cholesterol level as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with cyto‑reductive nephrectomy. BMC Cancer. 2017; 17(1): 364. doi:10.1186/s12885-017-3322-5.
47. Ishihara H, Kondo T, Yoshida K, et al. Evaluation of Preoperative Aspartate Transaminase/Alanine Transaminase Ratio as an Independent Predictive Biomarker in Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy: A Propensity Score Matching Study. Clin Genitourin Cancer. 2017; 15(5): 598–604. doi:10.1016/j.clgc.2017. 04. 011.
48. Laukhtina E, Pradere B, D`Andrea D, et al. Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. Urol Oncol Semin Orig Investig. 2020; 38(12): 936.e7–936.e14. doi:10.1016/j.urolonc.2020. 08. 013.
49. Culp SH, Schellhammer PF, Williams MB. Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER‑Based Study. Eur Urol. 2014; 65(6): 1058–1066. doi:10.1016/j.eururo.2013. 11. 012.
50. McIntosh AG, Umbreit EC, Holland LC, et al. Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy. Cancer. 2020; 126(17): 3950–3960. doi:10.1002/cncr.32991.
51. You D, Jeong IG, Song C, et al. Analysis of pre‑operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era. Jpn J Clin Oncol. 2015; 45(1): 96–102. doi:10.1093/jjco/hyu171.
52. Fukuda H, Takagi T, Kondo T, et al. Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy. Int J Clin Oncol. 2018; 23(3): 539–546. doi:10.1007/s10147-017-1221-z.
53. Marchioni M, Kriegmair M, Heck M, et al. Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi‑institutional Registry (REMARCC). Eur Urol Oncol. 2021; 4(2): 256–263. doi:10.1016/j.euo.2020. 12. 010.
54. Kutikov A, Uzzo RG, Caraway A, et al. Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int. 2009; 106(2): 218–223. doi:10.1111/j.1464-410X.2009.09079.x.
55. Culp SH, Tannir NM, Abel EJ, et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer. 2010; 116(14): 3378–3388. doi:10.1002/cncr.25046.
56. Bamias A, Tzannis K, Papatsoris A, et al. Prognostic Significance of Cytoreductive Nephrectomy in Patients With Synchronous Metastases From Renal Cell Carcinoma Treated With First‑Line Sunitinib: A European Multiinstitutional Study. Clin Genitourin Cancer. 2014; 12(5): 373–383. doi:10.1016/j.clgc.2014. 03. 012.
57. Zhao Z, Wu W, Duan X, Zeng G, Liu Y. The value of cytoreductive nephrectomy on the survival of metastatic renal carcinoma patients based on the number of site‑specific metastases. Kimple RJ, ed. PLoS One. 2019; 14(4): e0215861. doi:10.1371/journal.pone.0215861.
58. Choueiri TK, Xie W, Kollmannsberger C, et al. The Impact of Cytoreductive Nephrectomy on Survival of Patients With Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Targeted Therapy. J Urol. 2011; 185(1): 60–66. doi:10.1016/j.juro.2010. 09. 012.
59. Conti SL, Thomas I‑C, Hagedorn JC, et al. Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. Int J Cancer. 2014; 134(9): 2245–2252. doi:10.1002/ijc.28553.
60. Abern MR, Scosyrev E, Tsivian M, et al. Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted‑therapy era. Anticancer Res. 2014; 34(5): 2405–2411. http:// www.ncbi.nlm.nih.gov/pubmed/24778051.
61. Hanna N, Sun M, Meyer CP, et al. Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. J Clin Oncol. 2016; 34(27): 3267–3275. doi:10.1200/JCO.2016. 66. 7931.
62. Mathieu R, Pignot G, Ingles A, et al. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features. Urol Oncol Semin Orig Investig. 2015; 33(8): 339.e9–339.e15. doi:10.1016/j.urolonc.2015. 05. 014.
63. de Groot S, Redekop WK, Sleijfer S, et al. Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population‑based Registry. Urology. 2016; 95: 121–127. doi:10.1016/j.urology.2016. 04. 042.
64. Palumbo C, Mistretta FA, Knipper S, et al. Contemporary Cytoreductive Nephrectomy Provides Survival Benefit in Clear‑cell Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2020; 18(6): e730–e738. doi:10.1016/j.clgc.2020. 05. 009.
65. Warren M, Venner PM, North S, et al. A population‑based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment. Can Urol Assoc J. 2013; 3(4): 281. doi:10.5489/cuaj.1121.
66. Kroeger N, Xie W, Lee J‑L, et al. Metastatic non‑clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer. 2013; 119(16): 2999–3006. doi:10.1002/cncr.28151.
67. Alhalabi O, Karam JA, Tannir NM. Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology. Curr Opin Urol. 2019; 29(5): 521–525. doi:10.1097/MOU.0000000000000661.
68. Graham J, Wells JC, Donskov F, et al. Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol Oncol. 2019; 2(6): 643–648. doi:10.1016/j.euo.2019. 03. 007.
69. Adashek JJ, Zhang Y, Skelton WP, et al. Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation? Front Oncol. 2021; 10. doi:10.3389/fonc.2020.627025.
70. Blick C, Bott S, Muneer A, et al. Laparoscopic Cytoreductive Nephrectomy: A Three‑Center Retrospective Analysis. J Endourol. 2010; 24(9): 1451–1455. doi:10.1089/end.2009.0458.
71. Chapin BF, Delacroix SE, Culp SH, et al. Safety of Presurgical Targeted Therapy in the Setting of Metastatic Renal Cell Carcinoma. Eur Urol. 2011; 60(5): 964–971. doi:10.1016/j.eururo.2011. 05. 032.
72. Palumbo C, Knipper S, Dzyuba‑Negrean C, et al. Complication rates, failure to rescue and in‑hospital mortality after cytoreductive nephrectomy in the older patients. J Geriatr Oncol. 2020; 11(4): 718–723. doi:10.1016/j.jgo.2019. 06. 005.
73. Takagi T, Sugihara T, Yasunaga H, et al. Cytoreductive nephrectomy for metastatic renal cell carcinoma: A population‑based analysis of perioperative outcomes according to clinical stage. Int J Urol. 2014; 21(8): 770–775. doi:10.1111/iju.12446.
74. Stroup SP, Raheem OA, Palazzi KL, et al. Does Timing of Cytoreductive Nephrectomy Impact Patient Survival With Metastatic Renal Cell Carcinoma in the Tyrosine Kinase Inhibitor Era? A Multi‑institutional Study. Urology. 2013; 81(4): 805–812. doi:10.1016/j.urology.2012. 10. 054.
75. Powles T, Sarwar N, Stockdale A, et al. Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer. JAMA Oncol. 2016; 2(10): 1303. doi:10.1001/jamaoncol. 2016.1197.
76. Wallis CJD, Bjarnason G, Byrne J, et al. Morbidity and Mortality of Radical Nephrectomy for Patients With Disseminated Cancer: An Analysis of the National Surgical Quality Improvement Program Database. Urology. 2016; 95: 95–102. doi:10.1016/j.urology.2016. 04. 055.
77. Gershman B, Moreira DM, Boorjian SA, et al. Comprehensive Characterization of the Perioperative Morbidity of Cytoreductive Nephrectomy. Eur Urol. 2016; 69(1): 84–91. doi:10.1016/j.eururo.2015. 05. 022.
78. Pignot G, Thiery‑Vuillemin A, Walz J, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. 2020; 77(6): 761–763. doi:10.1016/j.eururo.2019. 12. 018.
79. Singla N, Margulis V. Re: Geraldine Pignot, Antoine Thiery‑Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.201. Eur Urol. 2020; 78(2): e79–e80. doi:10.1016/j.eururo.2020. 04. 025.
80. Mazzone E, Nazzani S, Preisser F, et al. Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma. Cancer Epidemiol. 2018; 56: 118–125. doi:10.1016/j. canep.2018. 08. 006.
81. Lenis AT, Salmasi AH, Donin NM, et al. Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma. Urol Oncol Semin Orig Investig. 2018; 36(2): 78.e21–78.e28. doi:10.1016/j.urolonc.2017. 09. 030.
82. Capitanio U, Zini L, Perrotte P, et al. Cytoreductive Partial Nephrectomy Does Not Undermine Cancer Control in Metastatic Renal Cell Carcinoma: A Population‑Based Study. Urology. 2008; 72(5): 1090–1095. doi:10.1016/j.urology.2008. 06. 059.
83. Hutterer GC, Patard J‑J, Colombel M, et al. Cytoreductive nephron‑sparing surgery does not appear to undermine disease‑specific survival in patients with metastatic renal cell carcinoma. Cancer. 2007; 110(11): 2428–2433. doi:10.1002/cncr.23054.
84. Krambeck AE, Leibovich BC, Lohse CM, et al. The Role of Nephron Sparing Surgery for Metastatic (pM1) Renal Cell Carcinoma. J Urol. 2006; 176(5): 1990–1995. doi:10.1016/j.juro.2006. 07. 015.
85. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer: A Combined Analysis. J Urol. 2004; 171(3): 1071–1076. doi:10.1097/01.ju.0000110610.61545.ae.
86. Chen J, He Q, Liu W, Li Y, Zhuang W. The Effect of Cytoreductive Partial Nephrectomy in Elderly Patients with Metastatic Renal Cell Carcinoma. Clin Interv Aging. 2020;Volume 15: 431–439. doi:10.2147/CIA.S243902.
87. Zlatev DV, Ozambela M, Salari K, et al. Trends and morbidity for minimally invasive versus open cytoreductive nephrectomy in the management of metastatic renal cell carcinoma. J Clin Oncol. 2018; 36(6_suppl): 632–632. doi:10.1200/JCO.2018. 36. 6_suppl.632.
88. Rabets JC, Kaouk J, Fergany A, et al. Laparoscopic versus open cytoreductive nephrectomy for metastatic renal cell carcinoma. Urology. 2004; 64(5): 930–934. doi:10.1016/j.urology.2004. 06. 052.
89. Eisenberg MS, Meng MV, Master VA, et al. Laparoscopic versus Open Cytoreductive Nephrectomy in Advanced Renal‑Cell Carcinoma. J Endourol. 2006; 20(7): 504–508. doi:10.1089/end.2006. 20. 504.
90. Ganeshappa A, Sundaram C, Lerner MA, Gardner TA. Role of the Laparoscopic Approach to Cytoreductive Nephrectomy in Metastatic Renal‑Cell Carcinoma: Does Size Matter? J Endourol. 2010; 24(8): 1289–1292. doi:10.1089/end.2009.0401.
91. Matin SF, Madsen LT, Wood CG. Laparoscopic cytoreductive nephrectomy: The M. D. Anderson Cancer Center experience. Urology. 2006; 68(3): 528–532. doi:10.1016/j.urology.2006. 03. 076.
92. Margulis V, Matin SF, Tannir N, et al. Surgical Morbidity Associated With Administration of Targeted Molecular Therapies Before Cytoreductive Nephrectomy or Resection of Locally Recurrent Renal Cell Carcinoma. J Urol. 2008; 180(1): 94–98. doi:10.1016/j.juro.2008. 03. 047.
93. Jackson BL, Fowler S, Williams ST. Perioperative outcomes of cytoreductive nephrectomy in the UK in 2012. BJU Int. 2015; 116(6): 905–910. doi:10.1111/bju.12890.
94. Nunez Bragayrac L, Hoffmeyer J, Abbotoy D, et al. Minimally invasive cytoreductive nephrectomy: a multi‑institutional experience. World J Urol. 2016; 34(12): 1651–1656. doi:10.1007/s00345-016-1827-1.
95. Zhao K, Kim E, Vetter J, et al. Laparoscopic cytoreductive nephrectomy is associated with significantly improved survival compared with open cytoreductive nephrectomy or targeted therapy alone. Mol Clin Oncol. 2020; 13(6): 1–1. doi:10.3892/mco.2020.2141.
96. Abel EJ, Spiess PE, Margulis V, et al. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus. J Urol. 2017; 198(2): 281–288. doi:10.1016/j.juro.2017. 03. 011.
97. Miyake H, Sugiyama T, Aki R, et al. Oncological outcomes after cytoreductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus. Int J Clin Oncol. 2018; 23(3): 553–558. doi:10.1007/s10147-017-1232-9.
98. Kwon T, Lee J‑L, You D, et al. Impact of surgery on the prognosis of metastatic renal cell carcinoma with IVC thrombus received TKI therapy. J Surg Oncol. 2014; 110(2): 145–150. doi:10.1002/jso.23612.
99. Kroeger N, Pantuck AJ, Wells JC, et al. Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies. Eur Urol. 2015; 68(3): 506–515. doi:10.1016/j.eururo.2014. 11. 054.
100. Gershman B, Thompson RH, Moreira DM, et al. Lymph Node Dissection is Not Associated with Improved Survival among Patients Undergoing Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Propensity Score Based Analysis. J Urol. 2017; 197(3 Part 1): 574–579. doi:10.1016/j.juro.2016. 09. 074.
101. Bhindi B, Wallis CJD, Boorjian SA, et al. The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and meta‑analysis. BJU Int. 2018; 121(5): 684–698. doi:10.1111/bju.14127.
102. Lughezzani G, Capitanio U, Jeldres C, et al. Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma. Cancer. 2009; 115(24): 5680–5687. doi:10.1002/cncr.24682.
103. Trinh Q‑D, Sukumar S, Schmitges J, et al. Effect of Nodal Metastases on Cancer‑specific Mortality After Cytoreductive Nephrectomy. Ann Surg Oncol. 2013; 20(6): 2096–2102. doi:10.1245/s10434-012-2806-4.
104. Bex A, Albiges L, Ljungberg B, et al. Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear‑cell Renal Cell Carcinoma. Eur Urol. 2018; 74(6): 805–809. doi:10.1016/j.eururo.2018. 08. 008.
105. Motzer RJ, Jonasch E, Boyle S, et al. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. J Natl Compr Cancer Netw. 2020; 18(9): 1160–1170. doi:10.6004/jnccn.2020.0043.
106. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‑up. Ann Oncol. 2019; 30(5): 706–720. doi:10.1093/annonc/mdz056.
Labels
Paediatric urologist Nephrology UrologyArticle was published in
Czech Urology
2022 Issue 1
Most read in this issue
- Antimicrobial resistance development – prevalence and antibiotic resistance patterns of bacterial strains in urine.
- Postpubertal teratoma with somatic‑type malignancy
- „Novinky“ v diagnostice karcinomu prostaty
- Rare case report of clear cell renal carcinoma of the right kidney with synchronous metastases in both ovaries